Reversible Mitochondrial Fragmentation in iPSC-Derived Cardiomyocytes from Children with DCMA, a Mitochondrial Cardiomyopathy
L. Rohani, P. Machiraju, R. Sabouny, G. Meng, S. Liu, T. Zhao, F. Iqbal, A. Ravandi, J. C. Wu, A. Khan, T. Shutt, D. Rancourt, S. C. Greenway
Abstract
BackgroundThe dilated cardiomyopathy with ataxia syndrome (DCMA) is an understudied autosomal recessive disease caused by loss-of-function mutations in the poorly characterized gene DNAJC19. Clinically, DCMA is commonly associated with heart failure and early death in affected children through an unknown mechanism. DCMA has been linked to Barth syndrome, a rare but well-studied disorder caused by deficient maturation of cardiolipin (CL), a key mitochondrial membrane phospholipid.\n\nMethodsPeripheral blood mononuclear cells from two children with DCMA and severe cardiac dysfunction were reprogrammed into induced pluripotent stem cells (iPSCs). Patient and control iPSCs were differentiated into beating cardiomyocytes (iPSC-CMs) using a metabolic selection strategy and mitochondrial structure and CL content before and after incubation with the mitochondrially-targeted peptide SS-31 were quantified.\n\nResultsPatient iPSCs carry the causative DNAJC19 mutation (rs137854888) found in the Hutterite population and the iPSC-CMs demonstrated highly fragmented and abnormally-shaped mitochondria associated with an imbalanced isoform ratio of the mitochondrial protein OPA1, an important regulator of mitochondrial fusion. These abnormalities were reversible by incubation with SS-31 for 24 hours. Differentiation of iPSCs into iPSC-CMs increased the number of CL species observed but consistent, significant differences in CL content were not seen between patients and control.\n\nConclusionsWe describe a unique and novel cellular model that provides insight into the mitochondrial abnormalities present in DCMA and identifies SS-31 as a potential therapeutic for this devastating disease.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SS-31 Reverses Mitochondrial Fragmentation in Fibroblasts from Patients with DCMA, a Mitochondrial Cardiomyopathy
P. Machiraju, X. Wang, … S. C. Greenway·bioRxiv·Jun 17, 2019
- SNTA1 GeneRescues Ion Channel Function in Cardiomyocytes Derived from Induced Pluripotent Stem Cells Reprogrammed from Muscular Dystrophy Patients with Arrhythmias
J. Jalife, E. N. Jimenez-Vazquez, … D. E. Michele·bioRxiv·Jan 25, 2022
- LMNA-Related Dilated Cardiomyopathy: Single-Cell Transcriptomics during Patient-derived iPSC Differentiation Support Cell type and Lineage-specific Dysregulation of Gene Expression and Development for Cardiomyocytes and Epicardium-Derived Cells with Lamin A/C Haploinsufficiency
Michael V. Zaragoza, Thuy-Anh Bui, … Qing Hua Nie·CellsPeer-reviewed·Sep 3, 2024
- Critical contribution of mitochondria in the development of cardiomyopathy linked to desmin mutation
Y. Hovhannisyan, Z. Li, … O. Agbulut·bioRxiv·Sep 14, 2023
- Recombinant annexin A6 promotes membrane repair in a stem cell derived-cardiomyocyte model of dystrophic cardiomyopathy
D. E. Fullenkamp, A. B. Willis, … E. M. McNally·bioRxiv·Mar 9, 2022
- Human iPSC-Based Model Reveals NOX4 as Therapeutic Target in Duchenne Cardiomyopathy
Robin Duelen, Domiziana Costamagna, … Maurilio Sampaolesi·Stem Cell ReportsPeer-reviewed·Jan 27, 2022